Only in Titles

Search results for: Polyclonal

paperclip

#34559854   2021/09/24 To Up

Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.

Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. In recent years, highly potent and/or broadly neutralizing human monoclonal antibodies (bnAbs) that are generated in chronic HIV-1 infections have been defined. These bnAbs exhibit atypical features such as extensive somatic hypermutations, long complementary determining region (CDR) lengths, tyrosine sulfation and presence of insertions/deletions, enabling them to effectively neutralize diverse HIV-1 viruses despite extensive variations within the core epitopes they recognize. As some of the HIV-1 bnAbs have evolved to recognize the dense viral glycans and cross-reactive epitopes (CREs), we assessed if these bnAbs cross-react with SARS-CoV-2. Several HIV-1 bnAbs showed cross-reactivity with SARS-CoV-2 while one HIV-1 CD4 binding site bnAb, N6, neutralized SARS-CoV-2. Furthermore, neutralizing plasma antibodies of chronically HIV-1 infected children showed cross neutralizing activity against SARS-CoV-2 pseudoviruses. Collectively, our observations suggest that human monoclonal antibodies tolerating extensive epitope variability can be leveraged to neutralize pathogens with related antigenic profile.
Nitesh Mishra, Sanjeev Kumar, Swarandeep Singh, Tanu Bansal, Nishkarsh Jain, Sumedha Saluja, Rajesh Kumar, Sankar Bhattacharyya, Jayanth Kumar Palanichamy, Riyaz Ahmad Mir, Subrata Sinha, Kalpana Luthra

2074 related Products with: Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.

100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized 100UG

Related Pathways

paperclip

#34557371   2021/08/20 To Up

A Case of Focal Segmental Glomerulosclerosis With Immune Complexes: Is HIV, Hepatitis B, or Crack the Culprit?

Human immunodeficiency virus (HIV)-positive individuals are at an increased risk for kidney diseases, including HIV-associated nephropathy (HIVAN), focal segmental glomerulosclerosis (FSGS), HIV immune complex disease of the kidney (HIVICK), and acute tubular necrosis (ATN). Non-modifiable factors such as age and genetics, as well as modifiable factors such as illicit drug use and compliance, define the progression to renal failure. The patient is a 64-year-old African American male with HIV, treated latent syphilis, chronic kidney disease stage 3a, and cocaine use disorder who presented with shortness of breath, bilateral lower extremities swelling, and fatigue with normal vitals and a physical exam remarkable for bibasilar inspiratory crackles with peripheral edema. Laboratory tests showed creatinine (Cr) of 2.23 mg/dL with a baseline of 1.5 mg/dL, albumin of 1.8, blood natriuretic peptide (BNP) of 667.88, and lipidemia. His urine was remarkable for proteinuria and microalbuminuria in the presence of cocaine. Immunofixation electrophoresis showed a marked increase in IgG and IgM, free lambda, and free kappa/free lambda ratio with HIV viral load of 39,400 copies/ml, absolute CD4 count of 56, and an acute hepatitis B panel. Renal biopsy confirmed HIVAN with FSGS accompanied by collapsing features, HIVICK, and ATN. The patient was subsequently started on highly active antiretroviral therapy (HAART) with prophylactic antibiotics and close monitoring.
Patil Balozian, Abdul Rahman Al Armashi, Mohammad Haidous, Massiel Cruz-Peralta, Keyvan Ravakhah

1299 related Products with: A Case of Focal Segmental Glomerulosclerosis With Immune Complexes: Is HIV, Hepatitis B, or Crack the Culprit?

100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#34557185   2021/09/07 To Up

Identification and Characterization of a Germline Mutation in CARD11 From a Chinese Case of B Cell Expansion With NF-κB and T Cell Anergy.

B cell expansion with NF-κB and T cell anergy (BENTA) is a rare primary immunodeficiency disorder caused by gain-of-function (GOF) mutations in the gene. Affected patients present with persistent B cell lymphocytosis in early childhood paired with lymphadenopathy and splenomegaly. Until now only six activating mutations from 14 patients have been reported in . Here we report a patient from China with polyclonal B cell lymphocytosis and frequent infections in early life. A heterozygous mutation (c.377G>A, G126D) in exon 5 of gene (NM_032415) was identified by whole exome sequencing. functional studies showed that the G126D mutation is associated with increased expression of CARD11 and NF-κB activation in Hela cells. Flow cytometry analysis indicated NK cell activity and CD107a degranulation of the patient were decreased. RNA sequencing analysis showed that a number of genes in NF-κB pathway increased while those involved in NK cell activity and degranulation were down-regulated. In summary, our work identified a germline GOF mutation in with functional evidence of BENTA.
Peiwei Zhao, Qingjie Meng, Yufeng Huang, Lei Zhang, Sukun Luo, Xiankai Zhang, Li Tan, Aifen Zhou, Hao Xiong, Xuelian He

2568 related Products with: Identification and Characterization of a Germline Mutation in CARD11 From a Chinese Case of B Cell Expansion With NF-κB and T Cell Anergy.



Related Pathways

paperclip

#34556486   2021/09/23 To Up

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.

To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19).
Reed Ac Siemieniuk, Jessica J Bartoszko, Juan Pablo Díaz Martinez, Elena Kum, Anila Qasim, Dena Zeraatkar, Ariel Izcovich, Sophia Mangala, Long Ge, Mi Ah Han, Thomas Agoritsas, Donald Arnold, Camila Ávila, Derek K Chu, Rachel Couban, Ellen Cusano, Andrea J Darzi, Tahira Devji, Farid Foroutan, Maryam Ghadimi, Assem Khamis, Francois Lamontagne, Mark Loeb, Anna Miroshnychenko, Sharhzad Motaghi, Srinivas Murthy, Reem A Mustafa, Gabriel Rada, Bram Rochwerg, Charlotte Switzer, Per O Vandvik, Robin Wm Vernooij, Ying Wang, Liang Yao, Gordon H Guyatt, Romina Brignardello-Petersen

2555 related Products with: Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.

100ug200ul100ul1000 tests100ug1000 tests100ug50 ug 200ug100ug50 ug 50 ug

Related Pathways

paperclip

#34555094   2021/09/23 To Up

Evaluation of the discriminatory potential of antibodies created from synthetic peptides derived from wheat, barley, rye and oat gluten.

C
David Poirier, Jérémie Théolier, Riccardo Marega, Philippe Delahaut, Nathalie Gillard, Samuel Benrejeb Godefroy

2814 related Products with: Evaluation of the discriminatory potential of antibodies created from synthetic peptides derived from wheat, barley, rye and oat gluten.

100 µg0.1 mg100 100 G100 U1 ml1 ml100.00 ug 100 G1000 TESTS/0.65ml

Related Pathways

    No related Items
paperclip

#34554727   2021/09/23 To Up

Chemiluminescence-Derived Self-Powered Photoelectrochemical Immunoassay for Detecting a Low-Abundance Disease-Related Protein.

Early diagnosis of cancers relies on the sensitive detection of specific biomarkers, but most of the current testing methods are inaccessible to home healthcare due to cumbersome steps, prolonged testing time, and utilization of toxic and hazardous substances. Herein, we developed a portable self-powered photoelectrochemical (PEC) sensing platform for rapid detection of prostate-specific antigen (PSA, as a model disease-related protein) by integrating a self-powered photoelectric signal output system catalyzed with chemiluminescence-functionalized Au nanoparticles (AuNPs) and a phosphomolybdic acid (PMA)-based photochromic visualization platform. TiO-g-CN-PMA photosensitive materials were first synthesized and functionalized on a sensor chip. The sensor consisted of filter paper modified with a photocatalytic material and a regional laser-etched FTO electrode as an alternative to a conventional PEC sensor with a glass-based electrode. The targeting system involved a monoclonal anti-PSA capture antibody-functionalized FeO magnetic bead (mAb-MB) and a polyclonal anti-PSA antibody (pAb)--(4-aminobutyl)--ethylisoluminol-AuNP (ABEI-AuNP). Based on the signal intensity of the chemiluminescent system, the photochromic device color changed from light yellow to heteropoly blue through the PMA photoelectric materials integrated into the electrode for visualization of the signal output. In addition, the electrical signal in the PEC system was amplified by a sandwich-type capacitor and readout on a handheld digital multimeter. Under optimum conditions, the sensor exhibited high sensitivity relative to PSA in the range of 0.01-50 ng mL with a low detection limit of 6.25 pg mL. The flow-through chemiluminescence reactor with a semiautomatic injection device and magnetic separation was avoid of unstable light source intensity inherent in the chemiluminescence process. Therefore, our strategy provides a new horizon for point-of-care analysis and rapid cost-effective clinical diagnosis.
Zhichao Yu, Hexiang Gong, Yuxuan Li, Jianhui Xu, Jin Zhang, Yongyi Zeng, Xiaolong Liu, Dianping Tang

1864 related Products with: Chemiluminescence-Derived Self-Powered Photoelectrochemical Immunoassay for Detecting a Low-Abundance Disease-Related Protein.

100.00 ug0.1 mg 50 ul100ug10ìg 100ul 100ul0.1ml (1mg/ml)200ul100 ug100ul0.1 mg

Related Pathways

paperclip

#34552950   2021/09/06 To Up

Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.


Alberto Alape-Girón, Andrés Moreira-Soto, Mauricio Arguedas, Hebleen Brenes, Willem Buján, Eugenia Corrales-Aguilar, Cecilia Díaz, Ann Echeverri, Marietta Flores-Díaz, Aarón Gómez, Andrés Hernández, María Herrera, Guillermo León, Román Macaya, José Arturo Molina-Mora, Javier Mora, Aarthi Narayanan, Alfredo Sanabria, Andrés Sánchez, Laura Sánchez, Álvaro Segura, Eduardo Segura, Daniela Solano, Claudio Soto, Jennifer L Stynoski, Mariángela Vargas, Mauren Villalta, Jan Felix Drexler, José María Gutiérrez

2100 related Products with: Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.

100 100 100.00 ug 100UG100 100 5 100UG100 µl100 1000 TESTS/0.65ml100ug/vial

Related Pathways

    No related Items
paperclip

#34552949   2021/09/06 To Up

High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern.

SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146-1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.
Andres Moreira-Soto, Mauricio Arguedas, Hebleen Brenes, Willem Buján, Eugenia Corrales-Aguilar, Cecilia Díaz, Ann Echeverri, Marietta Flores-Díaz, Aarón Gómez, Andrés Hernández, María Herrera, Guillermo León, Román Macaya, Arne Kühne, José Arturo Molina-Mora, Javier Mora, Alfredo Sanabria, Andrés Sánchez, Laura Sánchez, Álvaro Segura, Eduardo Segura, Daniela Solano, Claudio Soto, Jennifer L Stynoski, Mariángela Vargas, Mauren Villalta, Chantal B E M Reusken, Christian Drosten, José María Gutiérrez, Alberto Alape-Girón, Jan Felix Drexler

1241 related Products with: High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern.

0.1 ml4 Arrays/Slide2 Pieces/Box100 4 Membranes/Box100 2 Pieces/Box4 Membranes/Box2 Pieces/Box20 ug Product tipe: Antib200ug4 Arrays/Slide

Related Pathways

paperclip

#34552587   2021/09/06 To Up

The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease.

The closely related flaviviruses, dengue and Zika, cause significant human disease throughout the world. While cross-reactive antibodies have been demonstrated to have the capacity to potentiate disease or mediate protection during flavivirus infection, the mechanisms responsible for this dichotomy are still poorly understood. To understand how the human polyclonal antibody response can protect against, and potentiate the disease in the context of dengue and Zika virus infection we used intravenous hyperimmunoglobulin (IVIG) preparations in a mouse model of the disease. Three IVIGs (ZIKV-IG, Control-Ig and Gamunex) were evaluated for their ability to neutralize and/or enhance Zika, dengue 2 and 3 viruses . The balance between virus neutralization and enhancement provided by the neutralization data was used to predict the IVIG concentrations which could protect or enhance Zika, and dengue 2 disease . Using this approach, we were able to define the unique dynamics of complex polyclonal antibodies, allowing for both enhancement and protection from flavivirus infection. Our results provide a novel understanding of how polyclonal antibodies interact with viruses with implications for the use of polyclonal antibody therapeutics and the development and evaluation of the next generation flavivirus vaccines.
Amelia K Pinto, Mariah Hassert, Xiaobing Han, Douglas Barker, Trevor Carnelley, Emilie Branche, Tara L Steffen, E Taylor Stone, Elizabeth Geerling, Karla M Viramontes, Cory Nykiforuk, Derek Toth, Sujan Shresta, Shantha Kodihalli, James D Brien

1842 related Products with: The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease.

100 1 mg1 mg251,000 IU200 50 IU200 10 IU1 mg

Related Pathways

paperclip

#34549976   2021/09/22 To Up

Dengue virus serotype 1 conformational dynamics confers virus strain-dependent patterns of neutralization by polyclonal sera.

Dengue virus co-circulates globally as four serotypes (DENV1-4) that vary up to 40% at the amino acid level. Viral strains within a serotype further cluster into multiple genotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of vaccine design, and efforts to characterize epitopes targeted by polyclonal mixtures of antibodies are ongoing. Previously, we identified two E protein residues (126/157) that defined the serotype-specific antibody response to DENV1 genotype 4 strain West Pac-74. DENV1 and DENV2 human vaccine sera neutralized DENV1 viruses incorporating these substitutions equivalently. In this study, we explored the contribution of these residues in the neutralization of DENV1 strains representing distinct genotypes. While neutralization of the genotype 1 strain TVP2130 was similarly impacted by mutation at E residues 126/157, mutation of these residues in the genotype 2 strain 16007 did not markedly change neutralization sensitivity, indicating the existence of additional DENV1 type-specific antibody targets. The accessibility of antibody epitopes can be strongly influenced by the conformational dynamics of virions and modified allosterically by amino acid variation. We found that changes at E domain II residue 204, shown previously to impact access to a poorly accessible E domain III epitope, impacted sensitivity of DENV1 16007 to neutralization by vaccine immune sera. Our data identify a role for minor sequence variation in changes to the antigenic structure that impacts antibody recognition by polyclonal immune sera. Understanding how the many structures sampled by flaviviruses influences antibody recognition will inform the design and evaluation of DENV immunogens. Dengue virus (DENV) is an important human pathogen that co-circulates globally as four serotypes. Because sequential infection by different DENV serotypes is associated with more severe disease, eliciting a protective neutralizing antibody response against all four serotypes is a major goal of vaccine efforts. Here, we report that neutralization of DENV serotype 1 by polyclonal antibody is impacted by minor sequence variation among virus strains. Our data suggests mechanisms that control neutralization sensitivity extend beyond variation within antibody epitopes, but also include the influence of single amino acids on the ensemble of structural states sampled by structurally dynamic virions. A more detailed understanding of the antibody targets of DENV-specific polyclonal sera and factors that govern their access to antibody has important implications for flavivirus antigen design and evaluation.
Laura A VanBlargan, Pavle Milutinovic, Leslie Goo, Christina R DeMaso, Anna P Durbin, Stephen S Whitehead, Theodore C Pierson, Kimberly A Dowd

1777 related Products with: Dengue virus serotype 1 conformational dynamics confers virus strain-dependent patterns of neutralization by polyclonal sera.

100ug Lyophilized100μg100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized10001000100ug Lyophilized

Related Pathways